{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:03Z","timestamp":1794414423139,"version":"4.9.1"},"reference-count":372,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011692","name":"The Children's Cancer and Leukaemia Group","doi-asserted-by":"publisher","award":["CCLG 2024 22"],"award-info":[{"award-number":["CCLG 2024 22"]}],"id":[{"id":"10.13039\/100011692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022850","name":"Little Princess Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109120","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:07:17Z","timestamp":1789085237000},"page":"109120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["B-cell precursor acute lymphoblastic leukaemia: origins, classification, and therapeutic advances"],"prefix":"10.1016","volume":"288","author":[{"given":"Dylan","family":"Casey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Boyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109120_bb0005","first-page":"419","article-title":"Emerging monoclonal antibody therapy for the treatment of acute lymphoblastic leukemia","volume":"15","author":"Abuasab","year":"2021","journal-title":"Biologics: Targets and Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0010","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.molmed.2025.04.005","article-title":"Acute lymphoblastic leukemia relapse: Biomarkers, hopes, and challenges","volume":"31","author":"Adomako","year":"2025","journal-title":"Trends in Molecular Medicine"},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2026.109120_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2019-125340","article-title":"SWOG 1312 final results: A phase 1 trial of Inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed\/ refractory CD22+ acute leukemia","volume":"134","author":"Advani","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.mjafi.2023.11.011","article-title":"Expression of CRLF2 gene in childhood B lineage lymphoblastic leukemia: a prospective analytical study","volume":"81","author":"Agarwal","year":"2025","journal-title":"Medical Journal, Armed Forces India"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0030","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"The Lancet Haematology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0035","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1080\/10428194.2025.2541024","article-title":"Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: Incidence, biology, and treatment","volume":"66","author":"Agrawal","year":"2025","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12032-025-03124-2","article-title":"Menin inhibitors as targeted therapy in KMT2A-rearranged acute leukemia: a comprehensive review of current advances and therapeutic implications","volume":"43","author":"Ahmed","year":"2025","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0045","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0050","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/j.clml.2020.04.008","article-title":"Outcome of CD20-positive adult B-cell acute lymphoblastic leukemia and the impact of rituximab therapy","volume":"20","author":"Alduailej","year":"2020","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/leu.2014.322","article-title":"Clonal origins of ETV6-RUNX1+ acute lymphoblastic leukemia: Studies in monozygotic twins","volume":"29","author":"Alpar","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bib1707","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3324\/haematol.2024.286626","article-title":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: Clinical and genetic features of an emerging entity","volume":"110","author":"Alvey","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2018.03.001","article-title":"ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosis","volume":"224\u2013225","author":"Ampatzidou","year":"2018","journal-title":"Cancer Genetics"},{"issue":"7330","key":"10.1016\/j.pharmthera.2026.109120_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2010","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109120_bib1720","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: Results from children\u2019s oncology group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of Ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clinical Pharmacokinetics"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109120_bb0075","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cam4.221","article-title":"Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: A collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children\u2019s Cancer and Leukemia Study Group (CCLSG)","volume":"3","author":"Asai","year":"2014","journal-title":"Cancer Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0085","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-genom-120821-100535","article-title":"Extrachromosomal DNA in Cancer","volume":"23","author":"Bafna","year":"2022","journal-title":"Annual Review of Genomics and Human Genetics"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0095","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41375-025-02758-5","article-title":"DUX4-rearranged B-ALL: Deciphering a biological and clinical conundrum","volume":"39","author":"Bakewell","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0100","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bjh.19685","article-title":"Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia","volume":"205","author":"Bardini","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.2019002499","article-title":"Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia","volume":"135","author":"Barz","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109120_bib1722","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","article-title":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: Results of the GIMEMA LAL1913 trial","volume":"7","author":"Bassan","year":"2023","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bib1703","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s41375-022-01557-6","article-title":"UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment","volume":"36","author":"Bastian","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0110","first-page":"1113","article-title":"Ueber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren","author":"Behring","year":"1890","journal-title":"Deutch Med Woch"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13395-025-00388-0","article-title":"DUX4 at 25: How it emerged from \u201cjunk DNA\u201d to become the cause of facioscapulohumeral muscular dystrophy","volume":"15","author":"Belayew","year":"2025","journal-title":"Skeletal Muscle"},{"issue":"DEC","key":"10.1016\/j.pharmthera.2026.109120_bb0120","article-title":"RUNX1 mutations in inherited and sporadic leukemia","volume":"5","author":"Bellissimo","year":"2017","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bjh.19834","article-title":"Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia","volume":"206","author":"Bendig","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0130","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): A phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0135","article-title":"Proposals for the classification of the acute Leukaemias","volume":"451","author":"Bennett","year":"1976","journal-title":"British Journal of Haematofogy"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0140","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0145","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41375-021-01333-y","article-title":"Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study","volume":"35","author":"Boer","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bib1723","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood.2025029611","article-title":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: The GRAALL-2014 trial","volume":"147","author":"Boissel","year":"2026","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia invivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0155","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3324\/haematol.2023.283815","article-title":"Naked antibodies and antibody-drug conjugates: Targeted therapy for childhood acute lymphoblastic leukemia","volume":"109","author":"Brivio","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0160","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2020","journal-title":"Blood"},{"issue":"4793","key":"10.1016\/j.pharmthera.2026.109120_bb0165","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/1911114a0","article-title":"Evidence that the L-Asparaginase activity of Guinea pig serum is responsible for its antilymphoma effects","volume":"191","author":"Broome","year":"1961","journal-title":"Nature"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2021-147946","article-title":"A randomized phase 3 trial of Blinatumomab Vs. chemotherapy as post-reinduction therapy in Low Risk (LR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in Children and Adolescents\/Young Adults (AYAs): A report from children\u2019s oncology group stud\u2026","volume":"138","author":"Brown","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation-2017.1.13","article-title":"Minimal residual disease in adult ALL: Technical aspects and implications for correct clinical interpretation","volume":"2017","author":"Br\u00fcggemann","year":"2017","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0180","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41375-025-02599-2","article-title":"T-cell acute lymphoblastic leukaemia: Subtype prevalence, clinical outcome, and emerging targeted treatments","volume":"39","author":"Buckley","year":"2025","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0185","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease\u2013guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109120_bb0190","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.4161\/cc.10.20.17779","article-title":"Acute lymphoblastic leukemia and developmental biology: A crucial interrelationship","volume":"10","author":"Campos-Sanchez","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01672","article-title":"Targeting CXCR4 in AML and ALL","volume":"10","author":"Cancilla","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/diseases13070227","article-title":"Therapeutic implications of Menin inhibitors in the treatment of acute leukemia: A critical review","volume":"13","author":"Canichella","year":"2025","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0205","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3324\/haematol.2018.207019","article-title":"BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/1873-3468.70263","article-title":"The newfound relationship between extrachromosomal DNAs and excised signal circles","author":"Casey","year":"2026","journal-title":"FEBS Letters"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0215","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/leu.2017.127","article-title":"Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster","volume":"31","author":"Cazzaniga","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109120_bb0220","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1182\/blood-2011-07-366542","article-title":"Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia","volume":"118","author":"Cazzaniga","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0225","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/cancers16081580","article-title":"T-cell engagers\u2014The structure and functional principle and application in hematological malignancies","volume":"16","author":"Cech","year":"2024","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bb0230","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bib1717","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1080\/10428190802517732","article-title":"Augmented and standard Berlin-Frankfurt-M\u00fcnster chemotherapy for treatment of adult acute lymphoblastic leukemia","volume":"49","author":"Chang","year":"2008","journal-title":"Leukemia & Lymphoma"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb0235","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1182\/bloodadvances.2025016665","article-title":"Asciminib for relapsed or refractory Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"9","author":"Chanut","year":"2025","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-5-29","article-title":"Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia","volume":"5","author":"Chen","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0245","article-title":"Blinatumomab in pediatric B-acute lymphoblastic leukemia","volume":"16","author":"Cheng","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0250","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41375-018-0144-7","article-title":"New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment","volume":"32","author":"Cheung","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100466","article-title":"Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: Acute lymphoblastic Leukemias, mixed-phenotype acute Leukemias, myeloid\/lymphoid neoplasms with eosinophilia, dendritic\/histiocytic Neoplas\u2026","volume":"37","author":"Choi","year":"2024","journal-title":"Modern Pathology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0260","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2011.39.2613","article-title":"US Food and Drug Administration approval overview in metastatic breast cancer","volume":"30","author":"Cortazar","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0265","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/cancers16061164","article-title":"PAX5 alterations in a consecutive childhood B-cell acute lymphoblastic leukemia cohort treated using the ALL IC-BFM 2009 protocol","volume":"16","author":"\u010crepin\u0161ek","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0270","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: A comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0275","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41417-025-00939-z","article-title":"RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications","volume":"32","author":"Cumbo","year":"2025","journal-title":"Cancer Gene Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0280","article-title":"An unusual presentation of Extramedullary relapse following Blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"14","author":"Daghri","year":"2022","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0285","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.3390\/ijms22094426","article-title":"The bone marrow niche in B-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia","volume":"22","author":"Dander","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0290","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/bloodadvances.2025015936","article-title":"Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: When, how, who?","volume":"10","author":"Datta","year":"2026","journal-title":"Blood Advances"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0295","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"The Lancet Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0310","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40272-024-00634-w","article-title":"Inotuzumab ozogamicin: first pediatric approval","volume":"26","author":"Dhillon","year":"2024","journal-title":"Pediatric Drugs"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0315","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.3324\/haematol.2023.284853","article-title":"Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models","volume":"109","author":"Domka","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0320","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","article-title":"International consensus classification of acute lymphoblastic leukemia\/lymphoma","volume":"482","author":"Duffield","year":"2022","journal-title":"Virchows Archiv: An International Journal of Pathology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0330","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: Setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0335","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0340","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2016.202","article-title":"Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia","volume":"31","author":"Eldfors","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155161","article-title":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","volume":"254","author":"El-Tanani","year":"2024","journal-title":"Pathology, Research and Practice"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101733","article-title":"Childhood cancer: Survival, treatment modalities, late effects and improvements over time","volume":"71","author":"Erdmann","year":"2021","journal-title":"Cancer Epidemiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143303","article-title":"Mesenchymal stromal cells (MSCs): An ally of B-cell acute lymphoblastic leukemia (B-ALL) cells in disease maintenance and progression within the bone marrow hematopoietic niche","volume":"14","author":"Fallati","year":"2022","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bb0370","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0375","first-page":"187","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109120_bb0380","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"386","author":"Fo\u00e0","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0385","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.95.8.4584","article-title":"Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia","volume":"95","author":"Ford","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0390","first-page":"826","article-title":"The TEL-AML1 leukemia fusion gene dysregulates the TGF-\u03b2 pathway in early B lineage progenitor cells","volume":"119","author":"Ford","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"6427","key":"10.1016\/j.pharmthera.2026.109120_bb0395","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/363358a0","article-title":"In utero rearrangements in the trithorax-related oncogene in infant leukaemias","volume":"363","author":"Ford","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109120_bib1705","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01374","article-title":"B-ALL with t(5;14)(q31;q32); IGH-IL3 rearrangement and eosinophilia: A comprehensive analysis of a peculiar IGH-Rearranged B-ALL","volume":"9","author":"Fournier","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0400","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00277-026-06883-8","article-title":"Venetoclax and Blinatumomab for adult patients with relapsed\/refractory or MRD positive Ph-negative B-cell precursor ALL: Phase I part of the GMALL-BLIVEN trial","volume":"105","author":"Fransecky","year":"2026","journal-title":"Annals of Hematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0405","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V18.4.431.431","article-title":"Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-Mercaptopurine and methotrexate","volume":"18","author":"Frei","year":"1961","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0410","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/bmjonc-2024-000573","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): An updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0415","first-page":"1","article-title":"Excised DNA circles from V(D)J recombination promote relapsed leukaemia","volume":"2025","author":"Gao","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0420","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5581\/1516-8484.20130111","article-title":"Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6\/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: A case report","volume":"35","author":"Garcia","year":"2013","journal-title":"Revista Brasileira de Hematologia e Hemoterapia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0425","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1038\/s41467-025-59531-6","article-title":"CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition","volume":"16","author":"Garcia-Gimenez","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1150612","article-title":"The role of microenvironment in the initiation and evolution of B-cell precursor acute lymphoblastic leukemia","volume":"13","author":"Garcia-Gimenez","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0435","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0889-8588(05)70192-1","article-title":"The hyper-CVAD regimen in adult acute lymphocytic leukemia","volume":"14","author":"Garcia-Manero","year":"2000","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0440","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/imt.15.108","article-title":"Role of inotuzumab ozogamicin in the treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"George","year":"2016","journal-title":"Immunotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb0445","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2024-202005","article-title":"WU-CART-007 (WT-7), an allogeneic CAR T-cell targeting CD7 in relapsed\/refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL\/LBL): Phase 2 results","volume":"144","author":"Ghobadi","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0450","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0455","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: An international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0460","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.26225","article-title":"The rise and fall of Gakekeeper mutations? The BCR-ABL1T315I paradigm","volume":"118","author":"Gibbons","year":"2011","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109120_bb0465","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0470","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0475","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/biomedicines11030821","article-title":"Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia","volume":"11","author":"G\u00f3recki","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0480","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clml.2025.05.013","article-title":"A phase I\/II trial of Ruxolitinib with chemotherapy for patients with relapsed and\/or refractory Philadelphia-like acute lymphoblastic leukemia","volume":"25","author":"Goulart","year":"2025","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0485","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-018-0015-6","article-title":"A causal mechanism for childhood acute lymphoblastic leukaemia","volume":"18","author":"Greaves","year":"2018","journal-title":"Nature Reviews Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0490","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","article-title":"Leukemia in twins: Lessons in natural history","volume":"102","author":"Greaves","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2005","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mechanisms of Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0505","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nature Genetics"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0510","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard risk pediatric B-acute lymphoblastic leukemia","volume":"392","author":"Gupta","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0515","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1038\/s41375-022-01720-z","article-title":"Hyperdiploidy: The longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children","volume":"36","author":"Haas","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0520","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.leu.2402849","article-title":"Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases","volume":"17","author":"Harewood","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0525","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1023\/A:1008375931236","article-title":"Commentary the World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues","volume":"10","author":"Harris","year":"1999","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0530","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0535","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2014-08-569228","article-title":"Blood spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease","volume":"125","author":"Harrison","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0540","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of Ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurology and Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0545","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/cancers16050858","article-title":"Biological markers of high-risk childhood acute lymphoblastic leukemia","volume":"16","author":"He","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0550","series-title":"The clinical and genetic features of ETV6\/RUNX1-like acute lymphoblastic leukemia in pediatric: A multicenter retrospective study","author":"He","year":"2024"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0555","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10555-019-09841-1","article-title":"Insights into the prenatal origin of childhood acute lymphoblastic leukemia","volume":"39","author":"Hein","year":"2020","journal-title":"Cancer Metastasis Reviews"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109120_bb0560","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2019002215","article-title":"The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in \u22480.6% of healthy newborns","volume":"134","author":"Hein","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb0565","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0026-2014","article-title":"History and practice: Antibodies in infectious diseases","volume":"3","author":"Hey","year":"2015","journal-title":"Microbiology Spectrum"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0570","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","article-title":"Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno childhood ALL working group","volume":"35","author":"Hirabayashi","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0575","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO clinical practice guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Annals of Oncology"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109120_bb0580","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children\u2019s oncology group AALL1331: Phase III trial of Blinatumomab in Children, adolescents, and Young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0585","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of HYPODIPLOID acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bib1709","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.206961","article-title":"NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2","volume":"104","author":"Hormann","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0590","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41375-023-01992-z","article-title":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","volume":"37","author":"Hoshitsuki","year":"2023","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb0595","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2024-211905","article-title":"Blinatumomab combined with Venetoclax increasing the abundance of CD8 T cell and NK cell and improve the outcome in relapsed\/refractory B-cell acute lymphoblastic leukemia patients","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0600","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/ol.2020.11583","article-title":"Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments","volume":"20","author":"Huang","year":"2020","journal-title":"Oncology Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0605","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2014","journal-title":"Immunology and Cell Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0610","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41594-022-00806-7","article-title":"Gene regulation on extrachromosomal DNA","volume":"29","author":"Hung","year":"2022","journal-title":"Nature Structural & Molecular Biology"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109120_bib1731","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood-2015-02-580043","article-title":"Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine","volume":"125","author":"Hunger","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0615","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0620","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2024.08.005","article-title":"SOHO state of the art updates and next questions | approach to BCR::ABL1-like acute lymphoblastic leukemia","volume":"25","author":"Iacobucci","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/357027","article-title":"Imatinib: A breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemotherapy Research and Practice"},{"issue":"7954","key":"10.1016\/j.pharmthera.2026.109120_bb0630","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0635","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A -rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bib1733","series-title":"Treatment of older patients with ALL","volume":"45","author":"Jabbour","year":"2025"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109120_bb0640","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-Centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0645","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: Post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"The Lancet Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","article-title":"Olverembatinib after failure of tyrosine kinase inhibitors, including Ponatinib or Asciminib: A phase 1b randomized clinical trial","volume":"11","author":"Jabbour","year":"2025","journal-title":"JAMA Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0655","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: A single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"The Lancet Haematology"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109120_bb0660","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with Inotuzumab Ozogamicin combined with Mini-hyper-CVD, with or without Blinatumomab is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb0665","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A first-in-human phase 1 study of the Menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0670","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0675","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"Jabbour","year":"2024","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0680","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0685","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab Ozogamicin with Bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109120_bb0690","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.3390\/cancers16223722","article-title":"Measurable residual disease in hematological cancers","volume":"16","author":"Jamroziak","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0695","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease\u2013directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0700","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2009.42","article-title":"Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)\/TCF3-PBX1","volume":"23","author":"Jeha","year":"2009","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb0705","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2021-146393","article-title":"Real-world outcomes for pediatric and Young adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (ALL) treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) R\u2026","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0710","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mpo.2950190411","article-title":"Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia","volume":"19","author":"Jones","year":"1991","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0715","first-page":"55","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: Current evidence and place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood and Lymphatic Cancer: Targets and Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bib1710","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/gcc.22882","article-title":"Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP\u2010BFM acute lymphoblastic leukemia protocol","volume":"59","author":"Jung","year":"2020","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0720","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.acthis.2014.11.009","article-title":"Tripolar mitosis in human cells and embryos: Occurrence, pathophysiology and medical implications","volume":"117","author":"Kalatova","year":"2015","journal-title":"Acta Histochemica"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.04.012","article-title":"Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors","author":"Kang","year":"2025","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0730","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"American Journal of Hematology"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109120_bb0735","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0740","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0745","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0750","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109120_bb0755","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of Inotuzumab Ozogamicin, a CD22 monoclonal antibody in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0760","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0765","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0770","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40364-017-0088-5","article-title":"Diagnosis and treatment of CD20 negative B cell lymphomas","volume":"5","author":"Katchi","year":"2017","journal-title":"Biomarker Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0775","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","article-title":"Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers","volume":"52","author":"Kim","year":"2020","journal-title":"Nature Genetics"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109120_bb0780","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood.2023021501","article-title":"Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: A GRAALL study","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0785","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database","volume":"7","author":"Kim","year":"2018","journal-title":"Cancer Medicine"},{"issue":"8624","key":"10.1016\/j.pharmthera.2026.109120_bb0790","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(88)90867-7","article-title":"Evidence for an infective cause of childhood leukaemia: Comparison of a Scottish new town with nuclear reprocessing sites in Britain","volume":"332","author":"Kinlen","year":"1988","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0795","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70238","article-title":"Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia","volume":"9","author":"Kirchhoff","year":"2025","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0800","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molcel.2019.02.025","article-title":"Cut-and-run: A distinct mechanism by which V(D)J recombination causes genome instability","volume":"74","author":"Kirkham","year":"2019","journal-title":"Molecular Cell"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109120_bb0805","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO-24-01851","article-title":"High-dose methotrexate in Children and Young adults with ALL and lymphoblastic lymphoma: Results of the randomized phase III study UKALL 2011","volume":"43","author":"Kirkwood","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0810","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12885-021-07897-3","article-title":"Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia","volume":"21","author":"Kong","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2024.100204","article-title":"KMT2A-rearranged acute lymphoblastic leukaemia","volume":"4","author":"Kotecha","year":"2024","journal-title":"EJC Paediatric Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0820","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0022-3476(70)80147-0","article-title":"The need for chemotherapy after prolonged complete remission in acute leukemia of childhood","volume":"76","author":"Krivit","year":"1970","journal-title":"The Journal of Pediatrics"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0825","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0830","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jnci\/djj095","article-title":"Childhood leukemia incidence in Britain, 1974-2000: Time trends and possible relation to influenza epidemics","volume":"98","author":"Kroll","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0835","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1073\/pnas.92.4.949","article-title":"A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase","volume":"92","author":"Krynetski","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0840","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.199885","article-title":"B-lymphoblastic lymphoma with TCF3-PBX1 fusion gene","volume":"104","author":"Kubota-Tanaka","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb0845","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/sj.leu.2404628","article-title":"Tiling-resolution array-CGH reveals the pattern of DNA copy number alterations in acute lymphoblastic leukemia with 21q amplification: the result of telomere dysfunction and breakage\/fusion\/breakage cycles?","volume":"21","author":"Kuchinskaya","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0850","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0855","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of Tisagenlecleucel in pediatric and Young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0860","doi-asserted-by":"crossref","DOI":"10.18295\/2075-0528.1700","article-title":"A historical tale of two lymphomas: Part II: Non-Hodgkin lymphoma","volume":"15","author":"Lakhtakia","year":"2015","journal-title":"Sultan Qaboos University Medical Journal"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb0865","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab ozogamicin: First global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0870","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.2024024517","article-title":"How I treat postimmunotherapy relapsed B-ALL","volume":"145","author":"Lamble","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0875","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/bloodadvances.2022009480","article-title":"Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0880","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08820139.2012.732166","article-title":"Protection against cyclophosphamide-induced myelosuppression by ZPDC glycoprotein (24 kDa)","volume":"42","author":"Lee","year":"2013","journal-title":"Immunological Investigations"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb0885","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","article-title":"Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0890","first-page":"193","article-title":"Venetoclax plus blinatumoma as first line therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia","volume":"15","author":"Lei","year":"2025","journal-title":"Blood and Lymphatic Cancer: Targets and Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb0895","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.3390\/ijms23052755","article-title":"Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in Children","volume":"23","author":"Lejman","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb0900","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.3390\/ijms22189827","article-title":"Targeted therapy in the treatment of pediatric acute lymphoblastic leukemia\u2014Therapy and toxicity mechanisms","volume":"22","author":"Lejman","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109120_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102505","article-title":"A novel approach to understanding the role of TCF3 mutations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Lejman","year":"2025","journal-title":"Translational Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0910","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12920-020-0709-y","article-title":"Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL","volume":"13","author":"Lejman","year":"2020","journal-title":"BMC Medical Genomics"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0915","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/sj.leu.2404729","article-title":"Impact of SARS on development of childhood acute lymphoblastic leukaemia","volume":"21","author":"Li","year":"2007","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bb0920","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2021004895","article-title":"Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia","volume":"5","author":"Li","year":"2021","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0925","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s10555-024-10203-9","article-title":"Molecular and cellular mechanisms of chemoresistance in paediatric pre\u2013B cell acute lymphoblastic leukaemia","volume":"43","author":"Lill","year":"2024","journal-title":"Cancer Metastasis Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29194","article-title":"Leukaemia and lockdown: The delayed infection model of childhood acute lymphoblastic leukaemia and the COVID-19 pandemic","volume":"68","author":"Lillie","year":"2021","journal-title":"Pediatric Blood & Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb0935","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2017-05-742643","article-title":"New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Lilljebj\u00f6rn","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0940","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb0945","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08880018.2015.1087611","article-title":"De novo MYC and BCL2 double-hit B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in pediatric and Young adult patients associated with poor prognosis","volume":"32","author":"Liu","year":"2015","journal-title":"Pediatric Hematology and Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb0950","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: Results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bib1708","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00277-026-06957-7","article-title":"The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions","volume":"105","author":"Liu","year":"2026","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0955","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1309\/AJCPAN7BH5DNYWZB","article-title":"B-acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"144","author":"Loghavi","year":"2015","journal-title":"American Journal of Clinical Pathology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200889","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand","volume":"32","author":"Luanpitpong","year":"2024","journal-title":"Molecular Therapy Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb0965","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1038\/s41598-025-86148-y","article-title":"Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL","volume":"15","author":"Luo","year":"2025","journal-title":"Scientific Reports"},{"issue":"44","key":"10.1016\/j.pharmthera.2026.109120_bb0970","article-title":"Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. Science","volume":"6","author":"Ma","year":"2020","journal-title":"Advances"},{"issue":"35","key":"10.1016\/j.pharmthera.2026.109120_bb0975","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1200\/JCO.2009.27.4944","article-title":"Clinical implications of the Cancer genome","volume":"28","author":"MacConaill","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109120_bb0980","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb0985","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/sj.leu.2403101","article-title":"Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins","volume":"17","author":"Maia","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb0990","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: A phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bib1730","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): A phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"4_suppl","key":"10.1016\/j.pharmthera.2026.109120_bb0995","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS517","article-title":"Preclinical and phase 1\/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications","volume":"43","author":"Maron","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1000","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb1005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.1.1","article-title":"Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): Results of the randomized Graall-R 2005 study","volume":"126","author":"Maury","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1020","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1717506","article-title":"Efficacy of Inotuzumab Ozogamicin plus Ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"2021","author":"Micheva","year":"2021","journal-title":"Case Reports in Hematology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb1025","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1080\/10428194.2024.2353877","article-title":"Outcomes of patients aged \u226526 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials","volume":"65","author":"Minnema","year":"2024","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: The history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1035","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/cells10123322","article-title":"DUX4 role in Normal physiology and in FSHD muscular dystrophy","volume":"10","author":"Mocciaro","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1040","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41375-020-01100-5","article-title":"Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting","volume":"35","author":"Modvig","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trecan.2020.08.008","article-title":"Aneuploidy in cancer: Lessons from acute lymphoblastic leukemia","volume":"7","author":"Molina","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cancers14010032","article-title":"Near-Haploidy and low-Hypodiploidy in B-cell acute lymphoblastic leukemia: When less is too much","volume":"14","author":"Molina","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb1055","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/s41375-024-02329-0","article-title":"Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction","volume":"38","author":"Moorman","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb1060","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","article-title":"A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia","volume":"124","author":"Moorman","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109120_bb1065","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","article-title":"Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: A comparison of the MRC ALL97\/99 and UKALL2003 trials","volume":"31","author":"Moorman","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1070","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1073\/pnas.112218799","article-title":"Chromosome translocations and covert leukemic clones are generated during normal fetal development","volume":"99","author":"Mori","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb1075","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bib1714","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.210104","article-title":"Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation","volume":"104","author":"Mouttet","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2025.06.001","article-title":"SOHO state of the art updates and next questions | elderly acute lymphoblastic leukemia: Low-dose chemotherapy and immunotherapy combinations","volume":"25","author":"Moyer","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing\u2013MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"issue":"7191","key":"10.1016\/j.pharmthera.2026.109120_bb1090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR\u2013ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb1095","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"7337","key":"10.1016\/j.pharmthera.2026.109120_bb1100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb1105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V62.2.241.241","article-title":"Comparison of central nervous system prophylaxis with cranial radiation and intrathecal methotrexate versus intrathecal methotrexate alone in acute lymphoblastic leukemia","volume":"62","author":"Muriel","year":"1983","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bib1718","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1110","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: A children\u2019s oncology group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2025.06.013","article-title":"Chromosomal tethering and mitotic transcription promote ecDNA nuclear inheritance","author":"Nichols","year":"2025","journal-title":"Molecular Cell"},{"issue":"7330","key":"10.1016\/j.pharmthera.2026.109120_bb1120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature09733","article-title":"Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells","volume":"469","author":"Notta","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bib1711","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3324\/haematol.2020.250423","article-title":"DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch","volume":"106","author":"Novakova","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb1125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of Inotuzumab Ozogamicin in Children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s oncology group protocol AALL1621","volume":"40","author":"O\u2019Brien","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb1130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2016.69.6278","article-title":"Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia","volume":"35","author":"O\u2019Connor","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1778311","article-title":"Relapse in childhood B-cell precursor acute lymphoblastic leukemia: Insights from transcriptomic signatures of diagnostic bone marrow","volume":"16","author":"Oh","year":"2026","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb1140","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1016\/S2352-3026(25)00258-3","article-title":"Establishing a sustainable academic point-of-care network for CAR T-cell therapy","volume":"12","author":"Olesti","year":"2025","journal-title":"The Lancet Haematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb1145","first-page":"106","article-title":"Cytotoxic properties of cyclophosphamide: A focus on its mechanistic impacts on male gonadal functions","volume":"9","author":"Olowe","year":"2024"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.V80.1.203.203","article-title":"Formation of a Hyperdiploid karyotype in childhood acute lymphoblastic leukemia","volume":"80","author":"Onodera","year":"1992","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1155","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41375-024-02287-7","article-title":"ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?","volume":"38","author":"\u00d8stergaard","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb1160","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nature Reviews Disease Primers"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1170","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1541-7786.MCR-14-0056-T","article-title":"Cytoskeletal regulatory gene expression and migratory properties of B-cell progenitors are affected by the ETV6-RUNX1 rearrangement","volume":"12","author":"Palmi","year":"2014","journal-title":"Molecular Cancer Research: MCR"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb1175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bib1712","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2018-10-882142","article-title":"PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome","volume":"133","author":"Passet","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb1180","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.2023022919","article-title":"Genetic subtypes of B-cell acute lymphoblastic leukemia in adults","volume":"145","author":"Passet","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109120_bib1704","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.2021014723","article-title":"Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL","volume":"139","author":"Passet","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1185","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clinic Proceedings"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1190","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/gcc.20671","article-title":"High hyperdiploid childhood acute lymphoblastic leukemia","volume":"48","author":"Paulsson","year":"2009","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bib1713","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2025-760","article-title":"Unfavorable outcomes in pediatric PAX5r B-cell precursor acute lymphoblastic leukemia: FLT3 targeting as a potential novel treatment strategy","volume":"146","author":"Peccatori","year":"2025","journal-title":"Blood"},{"issue":"JUN","key":"10.1016\/j.pharmthera.2026.109120_bb1195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014The world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1200","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jama.1971.03180300032007","article-title":"Five-year follow-up of Total therapy of childhood lymphocytic leukemia","volume":"216","author":"Pinkel","year":"1971","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1205","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2141.1993.tb04665.x","article-title":"The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia","volume":"83","author":"Potter","year":"1993","journal-title":"British Journal of Haematology"},{"issue":"09","key":"10.1016\/j.pharmthera.2026.109120_bb1210","article-title":"Selective degradation of oncogenic extrachromosomal DNA by type I-E CRISPR","volume":"2025","author":"Poursani","year":"2025","journal-title":"BioRxiv"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb1215","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.leu.2401866","article-title":"Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax\/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo","volume":"14","author":"Prokop","year":"2000","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb1220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","article-title":"Precision medicine in acute lymphoblastic leukemia","volume":"14","author":"Pui","year":"2020","journal-title":"Frontiers of Medicine"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109120_bb1225","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Seminars in Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1235","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"561","key":"10.1016\/j.pharmthera.2026.109120_bb1240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba5942","article-title":"B cell acute lymphoblastic leukemia cells mediate RANK-RANKL\u2013dependent bone destruction","volume":"12","author":"Rajakumar","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109120_bb1245","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of phase II study of chemotherapy plus Dasatinib for the initial treatment of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bib1732","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: A children\u2019s oncology group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bb1250","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Rian","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb1255","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","article-title":"Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"6","author":"Ribera","year":"2022","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bib1729","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bib1724","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/bloodadvances.2021005624","article-title":"Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: The HOVON-100 trial","volume":"6","author":"Rijneveld","year":"2022","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/gcc.20412","article-title":"Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle","volume":"46","author":"Robinson","year":"2007","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1265","first-page":"215","article-title":"Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection","volume":"94","author":"Rosenberg","year":"2007","journal-title":"Advances in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1270","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1275","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nri1152","article-title":"Restraining the V(D)J recombinase","volume":"3","author":"Roth","year":"2003","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237738","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: Efficacy, toxicity, and practical considerations","volume":"14","author":"Rubinstein","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1285","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11864-022-00963-3","article-title":"In utero development and Immunosurveillance of B cell acute lymphoblastic leukemia","volume":"23","author":"R\u00fcchel","year":"2022","journal-title":"Current Treatment Options in Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb1290","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/gcc.22439","article-title":"Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia","volume":"56","author":"Russell","year":"2017","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bib1725","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb1295","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/bloodadvances.2016002725","article-title":"Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic\/myeloproliferative neoplasms","volume":"1","author":"Sakurai","year":"2017","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1300","article-title":"Influence of intensive Asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1305","series-title":"Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients","author":"Satwani","year":"2013"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1310","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0022-3476(67)80053-2","article-title":"Sequential therapy of acute leukemia in childhood","volume":"70","author":"Saunders","year":"1967","journal-title":"The Journal of Pediatrics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bib1701","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12308-023-00541-y","article-title":"B-lymphoblastic leukemia\/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination","volume":"16","author":"Schichman","year":"2023","journal-title":"Journal of Hematopathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.stem.2009.04.019","article-title":"TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia","volume":"5","author":"Schindler","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"31","key":"10.1016\/j.pharmthera.2026.109120_bb1320","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in philadelphia chromosome\u2013positive acute lymphoblastic leukemia: A children\u2019s oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1325","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1330","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000053","article-title":"Advances in B-cell precursor acute lymphoblastic leukemia genomics","volume":"2","author":"Schwab","year":"2018","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb1335","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1340","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S2352-3026(20)30179-4","article-title":"Hyper-CVAD: A regimen for all seasons","volume":"7","author":"Seftel","year":"2020","journal-title":"The Lancet Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/asheducation-2008.1.365","article-title":"Acute lymphoblastic leukemia: An historical perspective","volume":"2008","author":"Seibel","year":"2008","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1350","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3390\/ijms23074019","article-title":"Lineage conversion in pediatric B-cell precursor acute leukemia under Blinatumomab therapy","volume":"23","author":"Semchenkova","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1355","article-title":"The innovative bridge in Ph positivity- efficacy and side effect profile of Inotuzomab Ozogamicin and Ponatinib combination in relapsed PH-positive and PH-like ALL","volume":"2025","author":"Seshadri","year":"2025","journal-title":"OncoDaily Medical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"10299","key":"10.1016\/j.pharmthera.2026.109120_bb1365","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1375","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ajh.27329","article-title":"Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy","volume":"99","author":"Short","year":"2024","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1380","first-page":"705","article-title":"Spotlight on Tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: Clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2025.100710","article-title":"Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: A single-Centre cohort study","volume":"44","author":"Sidhu","year":"2026","journal-title":"The Lancet Regional Health - Southeast Asia"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109120_bb1390","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12098-023-04635-4","article-title":"Relapsed acute lymphoblastic leukemia","volume":"91","author":"Sidhu","year":"2023","journal-title":"Indian Journal of Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1395","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bib1706","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.70080","article-title":"IGH\u202f:: IL3 \u2010Rearranged B\u2010Cell precursor acute lymphoblastic leukemia with hypereosinophilia in a child with a novel PAX5 germline variant","volume":"64","author":"Urba\u0144ski","year":"2025","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109120_bb1400","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"JULY","key":"10.1016\/j.pharmthera.2026.109120_bb1405","article-title":"The ESC: The dangerous by-product of V(D)J recombination","volume":"10","author":"Smith","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1410","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discovery"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1415","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.leu.2403000","article-title":"Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: An emerging molecular cytogenetic subgroup","volume":"17","author":"Soulier","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1420","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/ijc.23281","article-title":"Temporal trends in the incidence rate of childhood cancer in Germany 1987-2004","volume":"122","author":"Spix","year":"2008","journal-title":"International Journal of Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1425","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00432-015-1982-6","article-title":"Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients\u2019 poor response to treatment and short-term relapse","volume":"141","author":"Stamati","year":"2015","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1430","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.leu.2404083","article-title":"Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome","volume":"20","author":"Stams","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41408-022-00613-9","article-title":"Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins","volume":"12","author":"Steiml\u00e9","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109120_bib1719","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb1445","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1450","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30842","article-title":"A PAX5 P80R pediatric B acute lymphoblastic leukemia with monocytic lineage switch at diagnosis: Deciphering classification ambiguity","volume":"71","author":"Strullu","year":"2024","journal-title":"Pediatric Blood & Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1455","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/s41375-024-02386-5","article-title":"Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?","volume":"38","author":"Stutterheim","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1460","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood.V60.4.948.948","article-title":"Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A pediatric oncology group study","volume":"60","author":"Sullivan","year":"1982","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109120_bb1465","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16367","article-title":"Pathogenesis of ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1470","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bb1475","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ni.3160","article-title":"Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia","volume":"16","author":"Swaminathan","year":"2015","journal-title":"Nature Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1480","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.3390\/cimb44080238","article-title":"RUNX1 and RUNX3 genes expression level in adult acute lymphoblastic leukemia\u2014A case control study","volume":"44","author":"Szmajda-Krygier","year":"2022","journal-title":"Current Issues in Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1485","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/hematology.2020000162","article-title":"What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?","volume":"2020","author":"Talleur","year":"2020","journal-title":"Hematology: the American Society of Hematology Education Program"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109120_bb9371","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/bjh.70130","article-title":"A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model","volume":"207","author":"Tamai","year":"2025","journal-title":"British Journal of Haematology"},{"issue":"8037","key":"10.1016\/j.pharmthera.2026.109120_bb1490","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-024-07802-5","article-title":"Enhancing transcription\u2013replication conflict targets ecDNA-positive cancers","volume":"635","author":"Tang","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109120_bib1715","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3324\/haematol.2023.283148","article-title":"TCF3::HLF acute lymphoblastic leukemia: Still challenging to cure thirty years later","volume":"108","author":"Tasian","year":"2023","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb1495","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","article-title":"A phase 2 study of Ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (AALL1521\/INCB18424-269): Biologic characteristics and minimal residual disease response of patients with non-CRLF2-rearranged JAK\u2026","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1500","series-title":"RAG Represents a Widespread Threat to the Lymphocyte Genome","author":"Teng","year":"2015"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bb1505","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1510","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41375-022-01714-x","article-title":"Central nervous system involvement in childhood acute lymphoblastic leukemia: Challenges and solutions","volume":"36","author":"Thastrup","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1515","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1520","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome\u2013positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109120_bb1525","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood.2023021705","article-title":"Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases","volume":"144","author":"Thorsson","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bib1728","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb1535","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood-2011-05-354266","article-title":"ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor","volume":"118","author":"Torrano","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109120_bb1540","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1\u2013positive childhood ALL","volume":"123","author":"Van Der Veer","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109120_bb1545","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Van Dongen","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1550","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.leu.2404925","article-title":"Non-specific amplification of patient-specific Ig\/TCR gene rearrangements depends on the time point during therapy: Implications for minimal residual disease monitoring","volume":"22","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1555","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70125","article-title":"Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study","volume":"9","author":"Verbeek","year":"2025","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109120_bb1560","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.3390\/ijms25094881","article-title":"The evolving landscape of Flowcytometric minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"Verbeek","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109120_bb1565","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.3390\/ijms26188774","article-title":"Age-driven genetic and epigenetic heterogeneity in B-ALL","volume":"26","author":"Veselinova","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1570","author":"Vora"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bib1721","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: Results of DFCI ALL Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1575","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","article-title":"Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia","volume":"1","author":"Waanders","year":"2020","journal-title":"Blood Cancer Discovery"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109120_bb1580","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb1585","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood-2025-1480","article-title":"Neomorphic chromatin engagement and epigenetic reprogramming by the IKZF1 N159Y tandem duplication mutant in b-acute lymphoblastic leukemia","volume":"146","author":"Wang\u2019ondu","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1590","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","article-title":"Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"108","author":"Wayne","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1595","article-title":"Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: Results from a real-world study","volume":"16","author":"Wen","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1600","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood.V94.3.1057.415k10_1057_1062","article-title":"Protracted and variable latency of acute lymphoblastic leukemia AfterTEL-AML1 gene fusion in UteroPresented at the American Society of Hematology meeting, held in Miami Beach, FL, December 4-8, 1998, and published as an abstract in blood 92:68a, 1998 (su\u2026)","volume":"94","author":"Wiemels","year":"1999","journal-title":"Blood"},{"issue":"228","key":"10.1016\/j.pharmthera.2026.109120_bb1605","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/adc.43.228.187","article-title":"Cyclic chemotherapy in childhood acute leukaemia","volume":"43","author":"Willoughby","year":"1968","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1610","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3904\/kjim.2022.401","article-title":"Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lympho-blastic leukemia: A prospective phase II study","volume":"38","author":"Won Baek","year":"2023","journal-title":"The Korean Journal of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-37356-5","article-title":"Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia","volume":"14","author":"Woodward","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1620","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev-pathmechdis-051821-114223","article-title":"Extrachromosomal DNA: An emerging Hallmark in human Cancer","volume":"17","author":"Wu","year":"2021","journal-title":"Annual Review of Pathology"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb1625","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2025-3367","article-title":"Adverse genetic alterations and their prognostic impact in Chinese b-ALL patients with DUX4 rearrangement","volume":"146","author":"Xia","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1630","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41392-025-02310-y","article-title":"Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL","volume":"10","author":"Xue","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1635","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V96.1.264","article-title":"Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia","volume":"96","author":"Yagi","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1640","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41422-024-01054-8","article-title":"Modern biology of extrachromosomal DNA: A decade-long voyage of discovery","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1645","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.771487","article-title":"Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: Genetic variation as a potential risk factor","volume":"12","author":"Yang","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109120_bib1734","doi-asserted-by":"crossref","first-page":"934442","DOI":"10.3389\/fimmu.2022.934442","article-title":"Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell thera\u2026","volume":"13","author":"Yang","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1650","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41576-022-00521-5","article-title":"Extrachromosomal DNA amplifications in cancer","volume":"23","author":"Yi","year":"2022","journal-title":"Nature Reviews Genetics"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109120_bb1655","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70326","article-title":"Recent developments and evolving therapeutic strategies in KMT2A-rearranged acute leukemia","volume":"13","author":"Yin","year":"2024","journal-title":"Cancer Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109120_bb1660","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","article-title":"ETV6\/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype","volume":"56","author":"Zaliova","year":"2017","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109120_bb1665","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3324\/haematol.2020.249094","article-title":"Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia","volume":"106","author":"Zaliova","year":"2020","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109120_bb1670","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/bloodadvances.2021005318","article-title":"A novel class of ZNF384 aberrations in acute leukemia","volume":"5","author":"Zaliova","year":"2021","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109120_bib1716","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2024.286111","article-title":"Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation","volume":"110","author":"Zeckanovic","year":"2025","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2026.109120_bb1675","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: First-in-human phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109120_bb1680","article-title":"Rearrangements of the KMT2A gene in acute leukemia in children - determination in whole genome sequencing data and clinical application","volume":"2025","author":"Zerkalenkova","year":"2025","journal-title":"OncoDaily Medical Journal"},{"key":"10.1016\/j.pharmthera.2026.109120_bb1685","doi-asserted-by":"crossref","first-page":"165","DOI":"10.36255\/exon-publications-leukemia-biomarkers-lymphoblastic-leukemia","article-title":"Prognostic and predictive biomarkers in precursor B-cell acute lymphoblastic leukemia","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109120_bb1690","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/cimb47120988","article-title":"Research progress on the KMT2A-AFF3 fusion gene in childhood acute lymphoblastic leukemia: Mechanisms, clinical implications, and therapeutic strategies","volume":"47","author":"Zhang","year":"2025","journal-title":"Current Issues in Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1695","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109120_bb1700","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: Current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:59:09Z","timestamp":1794412749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":372,"alternative-id":["S0163725826001476"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109120","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell precursor acute lymphoblastic leukaemia: origins, classification, and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109120"}}